Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Tokio Marine Asset Management Co. Ltd.

Tokio Marine Asset Management Co. Ltd. boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 15.4% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 35,439 shares of the biopharmaceutical company’s stock after buying an additional 4,742 shares during the quarter. Tokio Marine Asset Management Co. Ltd.’s holdings in Gilead Sciences were worth $2,971,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the business. Black Swift Group LLC purchased a new position in shares of Gilead Sciences during the 3rd quarter worth about $419,000. Curi RMB Capital LLC increased its position in Gilead Sciences by 0.9% during the third quarter. Curi RMB Capital LLC now owns 87,850 shares of the biopharmaceutical company’s stock worth $7,365,000 after purchasing an additional 805 shares during the last quarter. Zions Bancorporation N.A. raised its stake in Gilead Sciences by 6.8% during the third quarter. Zions Bancorporation N.A. now owns 115,611 shares of the biopharmaceutical company’s stock worth $9,693,000 after purchasing an additional 7,331 shares during the period. Plato Investment Management Ltd boosted its holdings in shares of Gilead Sciences by 5.1% in the 3rd quarter. Plato Investment Management Ltd now owns 50,821 shares of the biopharmaceutical company’s stock valued at $4,257,000 after purchasing an additional 2,468 shares during the last quarter. Finally, D Orazio & Associates Inc. purchased a new stake in shares of Gilead Sciences during the 3rd quarter valued at $245,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

GILD has been the topic of a number of research analyst reports. BMO Capital Markets lifted their target price on Gilead Sciences from $94.00 to $102.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Leerink Partners raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and raised their price target for the company from $74.00 to $96.00 in a report on Monday, October 21st. JPMorgan Chase & Co. upped their price objective on shares of Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Piper Sandler increased their target price on Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Finally, Cantor Fitzgerald boosted their price target on Gilead Sciences from $70.00 to $80.00 and gave the company a “neutral” rating in a report on Thursday, November 7th. Eleven analysts have rated the stock with a hold rating, ten have issued a buy rating and four have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $93.10.

Insider Activity

In other news, insider Merdad Parsey sold 25,590 shares of the stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the completion of the sale, the insider now owns 99,599 shares in the company, valued at approximately $9,113,308.50. This represents a 20.44 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the transaction, the insider now owns 78,127 shares in the company, valued at $6,545,480.06. The trade was a 27.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 56,947 shares of company stock worth $4,968,674. 0.16% of the stock is owned by company insiders.

Gilead Sciences Trading Down 0.6 %

NASDAQ:GILD opened at $92.11 on Friday. The stock has a market cap of $114.79 billion, a price-to-earnings ratio of 1,023.44, a PEG ratio of 2.85 and a beta of 0.17. The company has a debt-to-equity ratio of 1.24, a quick ratio of 0.82 and a current ratio of 1.26. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $98.90. The business has a fifty day moving average of $86.22 and a 200-day moving average of $75.69.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating the consensus estimate of $1.58 by $0.44. The firm had revenue of $7.55 billion for the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. Gilead Sciences’s quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter last year, the company earned $2.29 EPS. Equities analysts predict that Gilead Sciences, Inc. will post 4.39 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be paid a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 3.34%. The ex-dividend date is Friday, December 13th. Gilead Sciences’s payout ratio is currently 3,422.22%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.